Abstract
Cytos is to transfer its monoclonal antibody (mAb) technology platform, a specific application of the so-called DELphi™ technology, to Intercell for EUR 15 M.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
